Recombinant Type III Humanized Collagen for Cross-Linker-Free Gels
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing collagen-based materials for cosmetic surgery, such as silica gel prostheses, autologous tissue transplantation, and hydrogel injections, suffer from complications like infection, immune rejection, toxicity, and poor tissue compatibility, necessitating the development of a humanized collagen that is non-immunogenic, biocompatible, and capable of forming gels without cross-linking agents.
Innovation Solution
Development of recombinant type III humanized collagen polypeptides with specific N-terminal and C-terminal sequences (SEQ ID NO:1 and SEQ ID NO:2) that can form gels at low temperatures without cross-linking agents, using codon-optimized expression in E. coli and purification methods to create a biocompatible tissue filling and augmentation material.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If silica gel prostheses are used for tissue filling, then tissue compatibility and mechanical properties are improved, but wound infection and capsular contracture occur due to static electricity attracting dust and cilia
Solution Approach 1:
The patent extracts and eliminates the harmful static electricity property from the prosthesis surface by using a collagen-based material instead of silica gel, thereby removing the mechanism that attracts dust and cilia while maintaining the beneficial tissue compatibility
Solution Approach 2:
The patent changes the material composition parameter from silica gel to collagen polypeptide, which fundamentally alters the surface properties to eliminate static electricity attraction while maintaining structural integrity and biocompatibility
2Reliability
If autologous fat transplantation is used for tissue filling, then biocompatibility and immune compatibility are improved, but high absorption rate and low survival rate require multiple transplantations
Solution Approach 1:
The patent creates a synthetic collagen polypeptide that copies the beneficial biological properties of autologous tissue (biocompatibility, immune compatibility) without the drawbacks of fat absorption and deformation, providing a stable alternative that achieves desired effects in single transplantation
3Strength
If cross-linking agents are used to form collagen gels, then gel strength and stability are improved, but toxic side effects and immune responses occur
Solution Approach 1:
The patent enables the collagen polypeptide to perform self-crosslinking through its inherent chemical properties (aldehyde groups reacting with amino groups) without requiring external cross-linking agents, thereby achieving gel strength while eliminating toxic side effects
Solution Approach 2:
The patent uses natural biochemical reactions between aldehyde groups and amino groups as an intermediary mechanism to achieve crosslinking, replacing harmful chemical cross-linking agents with a biologically compatible reaction pathway
4Strength
If traditional collagen materials are used for tissue filling, then structural support is provided, but immune rejection and inflammatory responses occur
Solution Approach 1:
The patent modifies specific local regions of the collagen molecule (N-terminal and C-terminal sequences) to enhance immune compatibility while maintaining the triple-helix structural support function in the core regions
Solution Approach 2:
The patent creates a composite structure combining humanized collagen sequences with specific terminal modifications (including cell adhesion motifs and crosslinking sites) to achieve both structural integrity and immune compatibility
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The recombinant type III humanized collagen forms stable gels at low temperatures, providing effective tissue filling and augmentation with high biocompatibility and no immune response, suitable for applications like breast augmentation, rhinoplasty, and facial filling, and can be produced on a large scale.
Implementation Method 1
the recombinant type III humanized collagen forms stable gels at low temperatures
Implementation Method 2
capable of forming gels without cross-linking agents
Data Source
AI summary
Polypeptides and uses thereof are provided. The polypeptide includes an N-terminal sequence and a C-terminal sequence, wherein the N-terminal sequence includes one or more repeating units including the amino acid sequence shown in SEQ ID NO. 1. The use of a human structural material for tissue filling and augmentation is provided in the present disclosure, which is expected to have a wide range of applications in the fields such as breast augmentation, rhinoplasty and mid-face filling as it does not require transplantation from the human body, yet has the natural advantages of using human tissue for filling.